Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Updated: Sep 10 2024

Human Immunodeficiency Virus (HIV)

Images
https://upload.medbullets.com/topic/120251/images/hiv_virion-en-2.jpg
https://upload.medbullets.com/topic/120251/images/kaposisarcoma.jpg
  • Snapshot
    • A 44-year-old man presents to his primary care physician for 1 week of worsening malaise, myalgias, sore throat, and chills. He denies any sick contacts or recent travel history. His past medical history is noncontributory. He drinks alcohol occasionally, denies smoking, and is sexually active with 2 men and inconsistently uses condoms. In the past, he has been treated for chlamydia and gonorrhea. He consents for a fourth-generation combination HIV-1/2 immunoassay, which returns positive. An HIV-1/HIV-2 antibody differentiation immunoassay confirms the diagnosis and he is started on tenofovir alafenamide, emtricitabine, and bictegravir.
  • Introduction
    • Definition
      • a blood-borne virus that is transmitted via
        • sexual intercourse
        • sharing needles
        • vertical transmission from the mother to the fetus
    • Microbiology
      • enveloped virus
      • single-stranded positive-sense RNA retrovirus
      • genes
        • env gene leads to the production of gp160, which is cleaved to produce gp120 and gp41
          • gp120 attaches to the patient's CD4+ T-cells
          • gp41 leads to fusion and entry into the immune cell
        • gag gene leads to the production of p24 and p17
          • p24 - viral capsid
          • p17 - viral matrix proteins
        • pol gene leads to the production of
          • reverse transcriptase
          • aspartate protease
          • integrase
    • Associated conditions
      • opportunistic infections
      • malignancy
      • cognitive decline
      • cardiovascular disease
  • Epidemiology
    • Incidence
      • most commonly transmitted by sexual intercourse or sharing needles
  • ETIOLOGY
    • Pathogenesis
      • HIV attaches to the surface of CD4+ T-cells, along with either CXCR4 or CCR5 coreceptor binding
        • HIV enters the cell, uncoats, and its RNA is reverse transcribed (by reverse transcriptase) into DNA, which integrates into the host's genome, creating billions of viral particles, lysing the host cell, and releasing the viral particles into the bloodstream infecting other CD4+ T-cells
  • Opportunistic Infections
    • CD4+ Count < 500 mm3
        • Opportunistic Infection Based on CD4+ T-Cell Count
        • Opportunistic Infection
        • Findings
        • Prophylactic Treatment
        • Candida albicans
        • Oral thrush that is scrapable
        •  Pseudohyphae on microscopy
        • --
        • Epstein-Barr virus
        • Oral hairy leukoplakia:
        • not scrapable
        • --
        • HHV-8
        • Kaposi sarcoma
        • a palpable, nonpruritic lesion that is brown, pink, red, or violaceous in color
        • --
        • HPV
        • Squamous cell carcinoma of the:
        • anus (in men who have sex with men)
        • cervix
        • --
    • CD4+ Count < 200 mm3
        • Opportunistic Infection Based on CD4+ T-Cell Count
        • Opportunistic Infection
        • Findings
        • Prophylactic Treatment
        • Histoplasma capsulatum
        • Nonspecific findings such as:
        • fevers, night sweats, chills, and weight loss
        • dyspnea
        • nausea and vomiting
        •  Macrophages contain oval yeast cells
        • --
        • JC virus reactivation
        • Progressive multifocal leukoencephalopathy:
        • demyelinating disease of the central nervous system
        • --
        • Pneumocystis jirovecii
        • Pneumonia:
        • ground-glass opacity on chest radiography
        • Trimethoprim-sulfamethoxazole:
        • if contraindicated, can give dapsone, atovaquone, or pentamidine
        • Cryptosporidium parvum
        • Watery diarrhea
        • Nitazoxanide
    • CD4+ Count < 100 mm3
        • Opportunistic Infection Based on CD4+ T-Cell Count
        • Opportunistic Infection
        • Findings
        • Prophylactic Treatment
        • Aspergillus fumigatus
        • Hemoptysis
        •  Pleuritic chest pain
        • --
        • Bartonella henselae
        • Bacillary angiomatosis
        • angiomatous skin lesions
        • --
        • Candida albicans
        • Esophagitis
        • white plaques may appear on endoscopy
        • --
        • Cytomegalovirus 
        • Retinitis (can also be caused by HSV)
        •  Esophagitis 
        •  Colitis
        •  Pneumonitis
        •  Encephalitis
        •  Linear ulcers on endoscopy
        •  Fundoscopy may demonstrate cotton-wool spots
        •  Intranuclear inclusion bodies (owl eyes)
        • --
        • Cryptosporidium spp
        • Watery diarrhea
        •  Stool studies will show acid-fast oocysts 
        • --
        • Ebstein-Barr virus
        • B-cell lymphoma
        •  Central nervous system lymphoma
        • focal neurologic deficits
        • ring enhancing lesion on brain MRI
        • EBV+ in CSF PCR
        • --
        • Mycobacterium avium-intracellulare
        • Non-specific findings
        • fever
        • night sweats
        • weight loss
        • lymphadenitis
        • The goal is to initiate antiretroviral therapy as soon as possible
        •  Azithromycin
        • Toxoplasma gondii
        • Ring-enhancing brain abscesses
        • Trimethoprim-sulfamethoxazole 
        • if contraindicated, give dapsone, pyrimethamine, and leucovorin
        • Empiric pyrimethamine-sulfadiazine
          • indicated in patients  CD4 < 100 cells/µL, focal neurologic findings, and ring-enhancing lesions on head imaging
          • treat for 10-14 days then obtain follow-up head imaging.
          • Brain biopsy
          • If the patient fails to improve clinically or the size of the lesion does not change after 10-14 days on pyrimethamine-sulfadiazine, the next step would be a biopsy of the lesion.
  • Presentation
    • Symptoms/physical exam
      • acute retroviral syndrome
        • fever
        • lymphadenopathy
        • sore throat
        • rash
        • myalgia/arthralgia
        • weight loss
        • mucocutaneous ulcers
  • Studies
    • HIV serology
      • fourth-generation combination HIV-1/2 immunoassay
        • best initial test 
          • detects both
            • HIV-1 and HIV-2 antibodies
            • HIV p24 antigen
        • screening criteria <ol> <li>at least once for all patients age 15 to 65 regardless of risk factors</li> <li>men who have sex with men</li> <li>pregnant women</li> <li>IV drug users</li> <li>patients who engage in unprotected sex</li> <li>those diagnosed with another sexually transmitted disease (STD)</li> </ol> 
        • interpretation
          • if negative
            • the patient is HIV-negative and no further test is needed
          • if positive
            • perform an HIV-1/HIV-2 antibody differentiation immunoassay
              • confirms the diagnosis
              • determines if the patient is infected with HIV-1, HIV-2, or both viruses
              • if the differentiation immunoassay is negative or indeterminate
                • perform a viral load
    • Viral load (qRT-PCR)
      • used to determine the
        • amount of virus the patient has
        • response to antiretroviral therapy
      • a high viral load is associated with a poor prognosis
    • CD4+ T-cell count and percentage
      • used to determine
        • need for prophylactic medication to prevent the development of opportunistic infections
        • response to antiretroviral therapy
    • HIV genotyping
      • used to determine HIV mutations that can lead to antiretroviral drug resistance
  • Differential
    • Influenza infection and immunosuppression caused by medications
      • differentiating factor
        • negative HIV screening tests
        • few to no risk factors for developing HIV (e.g., having sex without the use of barrier contraception and sharing needles)
  • Treatment
    • HIV-infected breastfeeding mothers
      • preferred to use replacement feedings due to high risk for transmission to the infant
    • HIV-infected patients and vaccinations 
      • HIV is an indication for obtaining the following vaccines
        • pneumococcal
        • hepatitis A (if not already immune)
        • hepatitis B (if not already immune)
        • meningococcal
    • Medical
      • antiretroviral therapy
        • indication
          • first-line treatment for patients with HIV infection
        • drug regimen
          • 2 nucleoside reverse transcriptase inhibitors (e.g., tenofovir alafenamide and emtricitabine) and an integrase inhibitor (e.g., bictegravir)
        • comments
          • the choice of antiretroviral drugs is guided by drug resistance testing
          • the most common cause of treatment failure is nonadherence
        • Nucleoside reverse transcriptase inhibitors
          • abacavir
          • emtricitabine
          • lamivudine
          • tenofovir
          • zidovudine
        • Non-nucleoside reverse transcriptase inhibitors
          • efavirenz
          • nevirapine
        • Integrase inhibitors
          • bictegravir
          • dolutegravir
          • raltegravir
        • Protease inhibitors
          • indinavir
          • ritonavir
      • post-exposure prophylaxis
        • indication
          • first-line treatment given immediately after HIV exposure (such as in health care personnel)
            • initiate within 72 hours
        • drug regimen
          • tenofovir, emtricitabine, and raltegravir
          • tenofovir, emtricitabine, and dolutegravir
      • pre-exposure prophylaxis
        • indication
          • to prevent HIV infection in high-risk patients
        • drug regimen
          • tenofovir and emtricitabine
      • antiretroviral therapy in pregnancy
        • indication
          • first-line treatment for pregnant women
        • comment
          • women who are pregnant are treated the same as for nonpregnant patients; however, certain medications should be avoided
        • intrapartum management
          • HIV RNA ≤ 1000 copies/mL
            • mode of delivery
              • cesarean sections are not needed
          • HIV RNA > 1000 copies/mL
            • mode of delivery
              • if < 38 weeks, plan to perform a cesarean section at 38 weeks in order to prevent HIV exposure to the baby via rupture of membranes
            • drug regimen
              • intravenous zidovudine
        • postpartum management
          • indication
            • all infants born to HIV-infected mothers
          • drug regimen
            • mothers with HIV RNA < 50 copies/mL
              • zidovudine in the infant for 4 weeks
            • mothers with HIV RNA  50 copies/mL
              • zidovudine, lamivudine, and nevirapine in the infant for 6 weeks
  • Complications
    • Malignancy
    • Cardiovascular and pulmonary disease
    • HIV-associated dementia
      • cognitive deficits, behavioral changes, and diminished motor skills not attributable to another cause
      • cortical atrophy and symmetric, periventricular white matter lesions on T2-weighted MRI
    • Immune reconstitution inflammatory syndrome
      • results in paradoxical worsening of infectious symptoms due to immune recovery from antiretroviral therapy
        • treatment involves continuing antiretroviral therapy and symptomatic treatment (e.g., acetaminophen and a short course of steroids)
        • if acute infection, often will start treating infection before initiating antiretroviral therapy 
  • Prognosis
    • High mortality rate (> 90%) in untreated patients
Card
1 of 0
Question
1 of 21
Private Note